Literature DB >> 10418925

Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice.

S Katayama1, K Oda, T Ohgitani, T Hirahara, Y Shimizu.   

Abstract

The influence of antigenic forms of Aujeszky's disease virus (ADV) and adjuvant types on the production of IgG subclass antibodies in mice was investigated. Particulate antigen, inactivated ADV, alone induced IgG1 and lower IgG2a antibody production, while the antigen adsorbed onto aluminum phosphate gel (alum) enhanced IgG1 antibody production but suppressed IgG2a antibody production as well as solubilized ADV antigen adsorbed onto alum. QS21 saponin purified from Quillaja saponaria promoted the production of IgG1 and IgG2a antibodies in a large extent against the both particulate and soluble antigens, while this saponin has strong hemolytic activity. Lablaboside F saponin isolated from Dolichos lablab without hemolytic activity, also induced the production of large IgG1 and little IgG2a antibody against both antigens. Oil-based adjuvant, ISA70 of water-in-oil type and ISA25 of oil-in-water type, increased IgG1 and IgG2a antibodies against the both soluble and particulate antigens, whereas a combination of ISA25 and soluble antigen reduced IgG2a antibody response. These results indicate that IgG1 antibody production was not suppressed by a combination of antigenic form and adjuvant type, however, IgG2a antibody production was influenced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418925     DOI: 10.1016/s0264-410x(98)00499-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Advances in Infectious Disease Vaccine Adjuvants.

Authors:  Jingyi Fan; Shengbin Jin; Lachlan Gilmartin; Istvan Toth; Waleed M Hussein; Rachel J Stephenson
Journal:  Vaccines (Basel)       Date:  2022-07-13

2.  Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used.

Authors:  Carlos A Velikovsky; Fernando A Goldbaum; Juliana Cassataro; Silvia Estein; Raúl A Bowden; Laura Bruno; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

3.  QS-21: A Potent Vaccine Adjuvant.

Authors:  Daming Zhu; Wenbin Tuo
Journal:  Nat Prod Chem Res       Date:  2015-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.